Copyright
©The Author(s) 2025.
World J Hepatol. Nov 27, 2025; 17(11): 109051
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.109051
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.109051
Table 1 PANoptosis and cancer therapeutic strategies
| Potential therapeutic strategy | Name | Effect | Mechanism | Ref. |
| Traditional laboratory therapy | TNF-α/IFN-γ | - | Triggers a PANoptosis cascade, exhibiting anti-tumor activity | [44] |
| + | May promote immune escape by inhibiting T-cell function | - | ||
| KLX | - | Induces PANoptosis by altering ZBP1 conformation. | [26] | |
| PPDPF | - | Regulates TRIM21 to ubiquitinate RIPK1, further inhibiting HCC progression | [78] | |
| OTULIN | - | Inhibits FADD/RIPK1-mediated hepatocyte apoptosis, protecting liver cells and preventing liver inflammation and HCC | [77] | |
| DNASE1 L3 | - | Activates the AIM2 pathway, thereby inducing PANoptosis | [35] | |
| HMOX1 | + | Silencing reduces HCC resistance to sorafenib | [92] | |
| Fn-OMV/oHSV | - | Combined use enhances inflammatory responses and improves immune checkpoint blockade (ICB) efficacy | [93] | |
| ADAR1 | + | Blocking ADAR1 activates ZBP1-mediated PANoptosis, inhibiting tumorigenesis | [94] | |
| Novel nanotherapies | Bi2Sn2O7 | - | Through ultrasound-responsive catalytic effects, generates enhanced enzyme kinetic effects for HCC treatment and inhibition of later-stage lung metastasis; also targets mitochondrial disruption, disrupting energy metabolism and amplifying ROS levels | [95] |
| Fullerenols | - | Affects mitochondrial function and induces endoplasmic reticulum stress | [96] |
- Citation: Li MJ, Wen CL, Cheng HT, Lyu HN, Han YY. PANoptosis in hepatocellular carcinoma: Underlying mechanisms. World J Hepatol 2025; 17(11): 109051
- URL: https://www.wjgnet.com/1948-5182/full/v17/i11/109051.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i11.109051
